利莉与Insilico医药合作,进行人工智能药物开发. Lilly partners with Insilico Medicine for AI drug development deal.

伊利莉公司已经同意与香港的Insilico医药达成27亿美元的潜在协议, 以使用人工智能来发现新药. Eli Lilly has agreed to a potential $2.75 billion deal with Hong Kong-based Insilico Medicine to use AI for drug discovery. 利利将获得Insilico开发药物的权利, 该公司使用人工智能设计新疗法, 而Insilicos则根据药物成功而收到1亿1500万美元的预付款和额外支付. Lilly will gain rights to develop drugs created by Insilico, which uses artificial intelligence to design new therapies, while Insilico receives an upfront payment of $115 million and additional payments based on the drugs' success.